Patents by Inventor P. Dan Cook

P. Dan Cook has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 6828434
    Abstract: Novel amine compounds are provided by the present invention. Methods of preparing and using said novel amine compounds are also provided.
    Type: Grant
    Filed: July 10, 2002
    Date of Patent: December 7, 2004
    Assignee: ISIS Pharmaceuticals, Inc.
    Inventors: Muthiah Manoharan, P. Dan Cook
  • Patent number: 6624294
    Abstract: Methods for the regioselective alkylation at the 2′-hydroxy position over the 3′-hydroxy position of nucleosides and nucleoside analogs, forming 2′-O-ester modified compounds, are disclosed. Reduction and derivatization of the 2′-O-ester provides 2′-O-modified nucleosides and nucleoside analogs useful for the synthesis of oligomeric compounds having improved hybridization affinity and nuclease resistance.
    Type: Grant
    Filed: April 16, 2002
    Date of Patent: September 23, 2003
    Assignee: ISIS Pharmaceuticals, Inc.
    Inventors: Andrew M. Kawasaki, Allister S. Fraser, Muthiah Manoharan, P. Dan Cook, Thazha P. Prakash
  • Publication number: 20030153737
    Abstract: Novel amine compounds are provided by the present invention. Methods of preparing and using said novel amine compounds are also provided.
    Type: Application
    Filed: July 10, 2002
    Publication date: August 14, 2003
    Applicant: ISIS Pharmaceuticals, Inc.
    Inventors: Muthiah Manoharan, P. Dan Cook
  • Publication number: 20030078415
    Abstract: Methods for the regioselective alkylation at the 2′-hydroxy position over the 3′-hydroxy position of nucleosides and nucleoside analogs, forming 2′-O-ester modified compounds, are disclosed. Reduction and derivatization of the 2′-O-ester provides 2′-O-modified nucleosides and nucleoside analogs useful for the synthesis of oligomeric compounds having improved hybridization affinity and nuclease resistance.
    Type: Application
    Filed: April 16, 2002
    Publication date: April 24, 2003
    Inventors: Andrew M. Kawasaki, Allister S. Fraser, Muthiah Manoharan, P. Dan Cook, Thazha P. Prakash
  • Patent number: 6495671
    Abstract: Novel amine compounds are provided by the present invention. Methods of preparing and using said novel amine compounds are also provided.
    Type: Grant
    Filed: October 12, 2000
    Date of Patent: December 17, 2002
    Assignee: ISIS Pharmaceuticals, Inc.
    Inventors: Muthiah Manoharan, P. Dan Cook
  • Patent number: 6403779
    Abstract: Methods for the regioselective alkylation at the 2′-hydroxy position over the 3′-hydroxy position of nucleosides and nucleoside analogs, forming 2′-O-ester modified compounds, are disclosed. Reduction and derivatization of the 2′-O-ester provides 2′-O-modified nucleosides and nucleoside analogs useful for the synthesis of oligomeric compounds having improved hybridization affinity and nuclease resistance.
    Type: Grant
    Filed: January 8, 1999
    Date of Patent: June 11, 2002
    Assignee: ISIS Pharmaceuticals, Inc.
    Inventors: Andrew M. Kawasaki, Allister S. Fraser, Muthiah Manoharan, P. Dan Cook, Thazha P. Prakash
  • Patent number: 6399757
    Abstract: Novel amine compounds are provided by the present invention. Methods of preparing and using said novel amine compounds are also provided.
    Type: Grant
    Filed: October 12, 2000
    Date of Patent: June 4, 2002
    Assignee: ISIS Pharmaceuticals, Inc.
    Inventors: Muthiah Manoharan, P. Dan Cook
  • Patent number: 6235886
    Abstract: Oligonucleotide and nucleotide amine analogs and methods of preparing and using these compounds are provided by the present invention.
    Type: Grant
    Filed: March 9, 1995
    Date of Patent: May 22, 2001
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Muthiah Manoharan, P. Dan Cook
  • Patent number: 6197965
    Abstract: Novel compounds are constructed to include a central aromatic, aliphatic, or heterocyclic ring system. Attached to the central ring system are two linear groups having nitrogenous moieties that are derivatized with chemical functional groups. The ring system can include further nitrogenous moieties, either as ring atoms or on pendant groups attached to the ring, that may also be derivatized with chemical functional groups. The totality of the chemical functional groups imparts certain conformational and other properties to the these compounds. In accordance with certain embodiments of the invention, libraries of such compounds are prepared utilizing permutations and combinations of the chemical functional groups and the nitrogenous moieties to build complexity into the libraries.
    Type: Grant
    Filed: May 17, 1999
    Date of Patent: March 6, 2001
    Assignee: ISIS Pharmaceuticals, Inc.
    Inventors: P. Dan Cook, Haoyun An
  • Patent number: 6077954
    Abstract: Novel compounds having the formula: ##STR1## wherein the constituent variables are defined herein. The compounds are constructed to include a central aromatic, aliphatic, or heterocyclic ring system. Attached to the central ring system are two linear groups having nitrogenous moieties that are derivatized with chemical functional groups. The ring system can include further nitrogenous moieties, either as ring atoms or on pendant groups attached to the ring, that may also be derivatized with chemical functional groups. The totality of the chemical functional groups imparts certain conformational and other properties to the these compounds. In accordance with certain embodiments of the invention, libraries of such compounds are prepared utilizing permutations and combinations of the chemical functional groups and the nitrogenous moieties to build complexity into the libraries.
    Type: Grant
    Filed: August 1, 1996
    Date of Patent: June 20, 2000
    Assignee: ISIS Pharmaceuticals, Inc.
    Inventors: P. Dan Cook, Haoyun An
  • Patent number: 5948903
    Abstract: This invention relates to compounds based on the 3-deazapurines ring system and to methods for making such compounds. The invention also generally relates to the field of "antisense" agents, agents that are capable of specific hybridization with a nucleotide sequence of an RNA. The 3-deazapurine-containing compounds of this invention can be useful for modulating the activity of RNA when incorporated into oligonucleotides. Oligonucleotides and their analogs are used for a variety of therapeutic and diagnostic purposes, such as treating diseases, regulating gene expression in experimental systems, assaying for RNA and for RNA products through the employment of antisense interactions with such RNA, diagnosing diseases, modulating the production of proteins and cleaving RNA in site specific fashions.
    Type: Grant
    Filed: May 8, 1998
    Date of Patent: September 7, 1999
    Assignee: ISIS Pharmaceuticals, Inc.
    Inventors: P. Dan Cook, Oscar L. Acevedo, Robert S. Andrews
  • Patent number: 5834607
    Abstract: Novel amine compounds are provided by the present invention. Methods of preparing and using said novel amine compounds are also provided.
    Type: Grant
    Filed: December 22, 1994
    Date of Patent: November 10, 1998
    Assignee: ISIS Pharmaceuticals, Inc.
    Inventors: Muthiah Manoharan, P. Dan Cook
  • Patent number: 5750692
    Abstract: This invention relates to compounds based on the 3-deazapurines ring system and to methods for making such compounds. The invention also generally relates to the field of "antisense" agents, agents that are capable of specific hybridization with a nucleotide sequence of an RNA. The 3-deazapurine-containing compounds of this invention can be useful for modulating the activity of RNA when incorporated into oligonucleotides. Oligonucleotides and their analogs are used for a variety of therapeutic and diagnostic purposes, such as treating diseases, regulating gene expression in experimental systems, assaying for RNA and for RNA products through the employment of antisense interactions with such RNA, diagnosing diseases, modulating the production of proteins and cleaving RNA in site specific fashions.
    Type: Grant
    Filed: December 10, 1996
    Date of Patent: May 12, 1998
    Assignee: ISIS Pharmaceuticals, Inc.
    Inventors: P. Dan Cook, Oscar L. Acevedo, Robert S. Andrews
  • Patent number: 5587470
    Abstract: This invention relates to compounds based on the 3-deazapurines ring system and to methods for making such compounds. The invention also generally relates to the field of "antisense" agents, agents that are capable of specific hybridization with a nucleotide sequence of an RNA. The 3- deazapurine-containing compounds of this invention can be useful for modulating the activity of RNA when incorporated into oligonucleotides. Oligonucleotides and their analogs are used for a variety of therapeutic and diagnostic purposes, such as treating diseases, regulating gene expression in experimental systems, assaying for RNA and for RNA products through the employment of antisense interactions with such RNA, diagnosing diseases, modulating the production of proteins and cleaving RNA in site specific fashions.
    Type: Grant
    Filed: August 14, 1995
    Date of Patent: December 24, 1996
    Assignee: ISIS Pharmaceuticals, Inc.
    Inventors: P. Dan Cook, Oscar L. Acevedo, Robert S. Andrews
  • Patent number: 5459255
    Abstract: This invention presents novel purine-based compounds for inclusion into oligonucleotides. The compounds of the invention, when incorporated into oligonucleotides are especially useful as agents that are capable of specific hybridization with a nucleotide sequence of an RNA. Oligonucleotides are used for a variety of purposes, such as regulating gene expression in experimental systems, assaying for RNA and for RNA products through the employment of interactions with such RNA, diagnosing diseases, modulating the production of proteins, and cleaving RNA in site specific fashions. The compounds of the invention include novel heterocyclic bases, nucleosides, and nucleotides. When incorporated into oligonucleotides, the compounds of the invention can be useful for modulating the activity of RNA.
    Type: Grant
    Filed: November 29, 1993
    Date of Patent: October 17, 1995
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: P. Dan Cook, Kanda S. Ramasamy, Muthiah Manoharan
  • Patent number: 5457191
    Abstract: This invention relates to compounds based on the 3-deazapurines ring system and to methods for making such compounds. The invention also generally relates to the field of "antisense" agents, agents that are capable of specific hybridization with a nucleotide sequence of an RNA. The 3-deazapurine-containing compounds of this invention can be useful for modulating the activity of RNA when incorporated into oligonucleotides. Oligonucleotides and their analogs are used for a variety of therapeutic and diagnostic purposes, such as treating diseases, regulating gene expression in experimental systems, assaying for RNA and for RNA products through the employment of antisense interactions with such RNA, diagnosing diseases, modulating the production of proteins and cleaving RNA in site specific fashions.
    Type: Grant
    Filed: March 5, 1993
    Date of Patent: October 10, 1995
    Assignee: ISIS Pharmaceuticals, Inc.
    Inventors: P. Dan Cook, Oscar L. Acevedo, Robert S. Andrews
  • Patent number: 4619996
    Abstract: A chemical process for preparing 2-.beta.-D-ribofuranosylselenazole-4-carboxamide, comprises reacting 2,3,5-tri-O-benzoyl-.beta.-D-ribofuranosyl-1-carbonitrile with gaseous hydrogen selenide in a polar organic solvent.
    Type: Grant
    Filed: July 9, 1984
    Date of Patent: October 28, 1986
    Assignee: Warner-Lambert Company
    Inventors: P. Dan Cook, Dennis J. McNamara
  • Patent number: 4439604
    Abstract: Hydroxy, amino and sulfhydryl derivatives of 7-.beta.-D-arabinofuranosyl-7H-pyrrolo[2,3-d]pyrimidine, their corresponding esters and non-toxic pharmaceutically acceptable salts are produced by arabinofuranosylation of the requisite heterocycles with 2,3,5-tri-O-benzyl-.alpha.-D-arabinofuranosyl halide and further reaction to obtain the desired compounds. These water soluble compounds are resistant to adenosine deaminase and exhibit antiviral activity.
    Type: Grant
    Filed: June 24, 1982
    Date of Patent: March 27, 1984
    Assignee: Warner-Lambert Company
    Inventor: P. Dan Cook
  • Patent number: 4352795
    Abstract: Hydroxy, amino and sulfhydryl derivatives of 7-.beta.-D-arabinofuranosyl-7H-pyrrolo[2,3-d]pyrimidine, their corresponding esters and non-toxic pharmaceutically acceptable salts are produced by arabinofuranosylation of the requisite heterocycles with 2,3,5-tri-O-benzyl-.alpha.-D-arabinofuranosyl halide and further reaction to obtain the desireexhibit antiviral activity.
    Type: Grant
    Filed: January 29, 1981
    Date of Patent: October 5, 1982
    Assignee: Warner-Lambert Company
    Inventor: P. Dan Cook
  • Patent number: 4315000
    Abstract: Hydroxy, amino and sulfhydryl derivatives of 1-.beta.-D-arabinofuranosyl-1H-imidazo[4,5-c]pyridine, their corresponding esters and non-toxic pharmaceutically acceptable salts are produced by arabinofuranosylation of the requisite heterocycles with 2,3,5-tri-O-benzyl-.alpha.-D-arabinofuranosyl halide and further reaction to obtain the desired compounds. These water soluble compounds are resistant to adenosine deaminase and exhibit antiviral activity.
    Type: Grant
    Filed: July 7, 1980
    Date of Patent: February 9, 1982
    Assignee: Warner-Lambert Company
    Inventor: P. Dan Cook